Genprex, Inc. (GNPX)

2.2100 +0.0900 (+4.25%) At close: 04:00PM EDT

Genprex, Inc.

3300 Bee Cave Road
Suite 650-227
Austin, TX 78746
United States
877 774 4679
https://www.genprex.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 26

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. John Rodney Varner	Co-Founder, Chairman, President & CEO	886.97k	N/A	1957
Mr. Ryan M. Confer M.S.	Chief Financial Officer	606.57k	N/A	1982
Mr. David M. Schloss	Senior Vice President of Human Resources	N/A	N/A	N/A
Mr. Thomas C. Gallagher Esq.	Senior Vice President of Intellectual Property & Licensing	N/A	N/A	N/A
Dr. Mark S. Berger M.D.	Chief Medical Officer	N/A	N/A	1955
Dr. Suzanne Thornton-Jones	Senior Vice President of Regulatory Affairs & Quality	N/A	N/A	N/A
Dr. Jack A. Roth F.A.C.S., M.D.	Chairman of Scientific & Medical Advisory Board	N/A	N/A	N/A

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) that is in Phase 1/2 and 2 clinical trials to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002 for the treatment of type 1 diabetes, and GPX-003 for the treatment of type 2 diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.

Corporate Governance

Genprex, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.